700 related articles for article (PubMed ID: 29674251)
21. [Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomized trial].
Krupitskiĭ EM; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Blokhina EA; Silverman BL
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(5 Pt 2):3-11. PubMed ID: 22951790
[TBL] [Abstract][Full Text] [Related]
22. Initiation of extended release naltrexone (XR-NTX) for opioid use disorder prior to release from prison.
Friedmann PD; Wilson D; Hoskinson R; Poshkus M; Clarke JG
J Subst Abuse Treat; 2018 Feb; 85():45-48. PubMed ID: 28527855
[TBL] [Abstract][Full Text] [Related]
23. Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX): Who Will Respond?
Nunes EV; Krupitsky E; Ling W; Zummo J; Memisoglu A; Silverman BL; Gastfriend DR
J Addict Med; 2015; 9(3):238-43. PubMed ID: 25901451
[TBL] [Abstract][Full Text] [Related]
24. Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial.
Lee JD; McDonald R; Grossman E; McNeely J; Laska E; Rotrosen J; Gourevitch MN
Addiction; 2015 Jun; 110(6):1008-14. PubMed ID: 25703440
[TBL] [Abstract][Full Text] [Related]
25. Extended-release intramuscular naltrexone (VIVITROL®): a review of its use in the prevention of relapse to opioid dependence in detoxified patients.
Syed YY; Keating GM
CNS Drugs; 2013 Oct; 27(10):851-61. PubMed ID: 24018540
[TBL] [Abstract][Full Text] [Related]
26. The effects of extended-release injectable naltrexone and incentives for opiate abstinence in heroin-dependent adults in a model therapeutic workplace: A randomized trial.
Jarvis BP; Holtyn AF; DeFulio A; Koffarnus MN; Leoutsakos JS; Umbricht A; Fingerhood M; Bigelow GE; Silverman K
Drug Alcohol Depend; 2019 Apr; 197():220-227. PubMed ID: 30852374
[TBL] [Abstract][Full Text] [Related]
27. Opioid use and dropout in patients receiving oral naltrexone with or without single administration of injection naltrexone.
Sullivan MA; Bisaga A; Glass A; Mishlen K; Pavlicova M; Carpenter KM; Mariani JJ; Levin FR; Nunes EV
Drug Alcohol Depend; 2015 Feb; 147():122-9. PubMed ID: 25555621
[TBL] [Abstract][Full Text] [Related]
28. Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone: A Randomized Clinical Trial and Follow-up Study.
Latif ZE; Šaltyte Benth J; Solli KK; Opheim A; Kunoe N; Krajci P; Sharma-Haase K; Tanum L
JAMA Psychiatry; 2019 Feb; 76(2):127-134. PubMed ID: 30566177
[TBL] [Abstract][Full Text] [Related]
29. Association between methadone or buprenorphine use during medically supervised opioid withdrawal and extended-release injectable naltrexone induction failure.
Shulman M; Choo TH; Scodes J; Pavlicova M; Wai J; Haenlein P; Tofighi B; Campbell ANC; Lee JD; Rotrosen J; Nunes EV
J Subst Abuse Treat; 2021 May; 124():108292. PubMed ID: 33771287
[TBL] [Abstract][Full Text] [Related]
30. Withdrawal severity and early response to treatment in the outpatient transition from opioid use to extended release naltrexone.
Mannelli P; Swartz M; Wu LT
Am J Addict; 2018 Sep; 27(6):471-476. PubMed ID: 30028058
[TBL] [Abstract][Full Text] [Related]
31. Cocaine use reduction with buprenorphine (CURB): rationale, design, and methodology.
Mooney LJ; Nielsen S; Saxon A; Hillhouse M; Thomas C; Hasson A; Stablein D; McCormack J; Lindblad R; Ling W
Contemp Clin Trials; 2013 Mar; 34(2):196-204. PubMed ID: 23159524
[TBL] [Abstract][Full Text] [Related]
32. Patients' perspectives on initiating treatment with extended-release naltrexone (XR-NTX).
Gauthier P; Greco P; Meyers-Ohki S; Desai A; Rotrosen J
J Subst Abuse Treat; 2021 Mar; 122():108183. PubMed ID: 33162260
[TBL] [Abstract][Full Text] [Related]
33. Is extended release naltrexone superior to buprenorphine-naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial.
Roache JD; Pavlicova M; Campbell A; Choo TH; Peavy M; Kermack AS; Nunes EV; Rotrosen J
Alcohol Clin Exp Res; 2021 Dec; 45(12):2569-2578. PubMed ID: 34698397
[TBL] [Abstract][Full Text] [Related]
34. Open-label Study of Injectable Extended-release Naltrexone (XR-NTX) in Healthcare Professionals With Opioid Dependence.
Earley PH; Zummo J; Memisoglu A; Silverman BL; Gastfriend DR
J Addict Med; 2017; 11(3):224-230. PubMed ID: 28358754
[TBL] [Abstract][Full Text] [Related]
35. Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: a randomized controlled trial.
DeFulio A; Everly JJ; Leoutsakos JM; Umbricht A; Fingerhood M; Bigelow GE; Silverman K
Drug Alcohol Depend; 2012 Jan; 120(1-3):48-54. PubMed ID: 21782353
[TBL] [Abstract][Full Text] [Related]
36. Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism.
Nunes EV; Bisaga A; Krupitsky E; Nangia N; Silverman BL; Akerman SC; Sullivan MA
Addiction; 2020 Feb; 115(2):239-246. PubMed ID: 31313402
[TBL] [Abstract][Full Text] [Related]
37. Extended-release naltrexone for youth with opioid use disorder.
Mitchell SG; Monico LB; Gryczynski J; Fishman MJ; O'Grady KE; Schwartz RP
J Subst Abuse Treat; 2021 Nov; 130():108407. PubMed ID: 34118699
[TBL] [Abstract][Full Text] [Related]
38. Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended-release naltrexone in a residential setting.
Mannelli P; Douaihy AB; Akerman SC; Legedza A; Fratantonio J; Zavod A; Sullivan MA
Am J Addict; 2022 Mar; 31(2):142-147. PubMed ID: 35137481
[TBL] [Abstract][Full Text] [Related]
39. Healthcare utilization and costs associated with treatment for opioid dependence.
Shah A; Duncan M; Atreja N; Tai KS; Gore M
J Med Econ; 2018 Apr; 21(4):406-415. PubMed ID: 29320915
[TBL] [Abstract][Full Text] [Related]
40. Effects of injectable extended-release naltrexone (XR-NTX) for opioid dependence on residential rehabilitation outcomes and early follow-up.
Leslie DL; Milchak W; Gastfriend DR; Herschman PL; Bixler EO; Velott DL; Meyer RE
Am J Addict; 2015 Apr; 24(3):265-270. PubMed ID: 25655226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
